Table 3.

Frequencies of MYCN amplification in 3251 patients with neuroblastoma^a by trial

Trial	N	Stage 1–3		Stage 4S		Stage 4 and aged <18 mo		Stages 1–3/4S/4 aged <18 mo		Stage 4 and aged ≥18 mo		All
		n/N	%	n/N	%	n/N	%	n/N	%	n/N	%	n/N	%
NB90	630	30/301	10.0	8/62	12.9	25/65	38.5	63/428	14.7	60/202	29.7	123/630	19.5
NB97	1174	56/684	8.2	10/111	9.0	41/101	40.6	107/896	11.9	75/278	27.0	182/1174	15.5
NB2004	1447	59/714	8.2	21/175	12.0	52/130	40.0	132/1019	13.0	150/428	35.0	282/1447	19.5
All	3251	145/1699	8.5	39/348	11.2	118/296	39.9	302/2343	12.9	285/909	31.3	587/3251	18.1

n number of patients with MYCN amplification per group, N number of patients per group (stage, age)

^a MYCN data missing in additional 398 patients (10.9%)